Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone

Translational Research

Volumn 153, Issue 6, 2009, Pages 275-282

  McTavish, Hugh ^a   Griffin, Robert J ^b   Terai, Kaoru ^c   Dudek, Arkadiusz Z ^c  

^a IGF Oncology LLC   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LONG R3 SOMATOMEDIN C; METHOTREXATE; SOMATOMEDIN; SOMATOMEDIN C DERIVATIVE; SOMATOMEDIN METHOTREXATE CONJUGATE; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; LOW DRUG DOSE; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TARGET CELL; TISSUE DISTRIBUTION;

EID: 65549090432     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.02.005     Document Type: Article

References (39)

1. Sachdev D., and Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6 (2007) 1-12
2. Dziadziuszko R., Camidge D.R., and Hirsch F.R. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 3 (2008) 815-818
3. Freund G.G., Kulas D.T., Way B.A., and Mooney R.A. Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines. Cancer Res 54 (1994) 3179-3185
4. Thulasi R., Dias P., Houghton P.J., and Houghton J.A. Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor. Cell Growth Differ 7 (1996) 531-541
5. Armengol G., Knuutila S., Lluis F., Capella G., Miro R., and Caballin M.R. DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet Cytogenet 116 (2000) 133-141
6. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplaisa 5 (2000) 95-105
7. Hakam A, Yeatman TJ, Lu L, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Human Pathol 199;30:1128-33.
8. Rotsch M., Maasberg M., Erbil C., Jaques G., Worsch U., and Havemann K. Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines. J Cancer Res Clin Oncol 1992 118 (1992) 502-508
9. Pandini G., Mineo R., Frasca F., et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65 (2005) 1849-1857
10. Schilsky R.L., and Ordway F.S. Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells. Cancer Chemother Pharmacol 15 (1985) 272-277
11. Kanter-Lewensohn L., Dricu A., Wang M., Wejde J., Kiessling R., and Larsson O. Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target. Melanoma Res 8 (1998) 389-397
12. Sell C., Baserga R., and Rubin R. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55 (1995) 303-306
13. Martin J.L., and Baxter R.C. IGF binding proteins as modulators of IGF action. In: Roberts C.T., and Rosenfeld R.G. (Eds). The IGF System: molecular biology, physiology, and clinical applications (1999), Humana Press, Totowa, NJ 227-256
14. Stewart C.E.H., and Rotwein P. Growth, differentiation and survival: multiple physiological functions for insulin-like growth factors. Physiological Revs 76 (1996) 1005-1026
15. Yakar S., Wu Y., Setser J., and Rosen C.J. The role of circulating IGF-I. Endocrine 19 (2002) 239-248
16. Chow J.C., Condorelli G., and Smith R.J. Insulin-like growth factor-I receptor internalization regulates signaling via the Shc/mitogen-activated protein kinase pathway but not the insulin receptor substate-1 pathway. J Biol Chem 273 (1998) 4672-4680
17. Furlanetto R.W. Receptor-mediated endocytosis and lysosomal processing of insulin-like growth factor I by mitogenically responsive cells. Endocrinology 122 (1988) 2044-2053
18. Carpentier J.L. Insulin receptor internalization: molecular mechanisms and physiopathological implications. Diabetologia 37 (1994) S117-S124
19. Paccaud J.P., Siddle K., and Carpentier J.L. Internalization of the human insulin receptor. J Biol Chem 267 (1992) 13101-13106
20. Francis G.L., Ross M., Ballard F.J., et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 8 (1992) 213-223
21. Ngo T.H., Barnard R.J., Leung P.S., Cohen P., and Aronson W.J. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144 (2003) 2319-2324
22. Tomas F.M., Knowles S.E., Chandler C.S., Francis G.L., Owens P.C., and Ballard F.J. Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. J Endocrinol 137 (1993) 413-421
23. Haluska P., Carboni J.M., TenEyck C., et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 7 (2008) 2589-2598
24. Blum G., Gazit A., and Levitzki A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 39 (2000) 15705-15712
25. Blum G., Gazit A., and Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 278 (2003) 40442-40454
26. Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., and Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64 (2004) 236-242
27. Arteaga C.L., Kitten L.J., Coronado E.B., et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84 (1989) 1418-1423
28. Maloney E.K., McLaughlin J.L., Dagdigian N.E., et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63 (2003) 5073-5083
29. Burtrum D., Zhu Z., Lu D., et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63 (2003) 8912-8921
30. Lacy M.Q., Alsina M., Fonseca R., et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26 (2008) 3196-3203
31. Haluska P., Shaw H.M., Batzel G.N., et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13 (2007) 5834-5840
32. Cohen B.D., Baker D.A., Sdorstrom C., et al. Combination therapy enhances the inhibition of tumor growth with fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11 (2005) 2063-2073
33. Sachdev D., Li S.L., Hartell J.S., Fuwita-Yamaguchi Y., Miller J.S., and Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63 (2003) 627-635
34. Bartucci M., Morelli C., Mauro L., Andò S., and Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 61 (2001) 6747-6754
35. Nickerson T., Chang F., Lorimer D., Smeekens S.P., Sawyers C.L., and Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 1 (2001) 6276-6280
36. Kimura G., Kasuya J., Giannini S., et al. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int J Urol 3 (1996) 39-46
37. Yee D. The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res Treat 32 (1994) 85-95
38. García-Echeverría C., Pearson M.A., Marti A., et al. In vivo antitumor activity of NVP-AEW541-A novel, potent and selective inhibitor the IGF-IR kinase. Cancer Cell 5 (2004) 231-239
39. Tanno B., Mancini C., Vitali R., Mancuso M., McDowell H.P., and Dominici C. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 12 (2006) 6772-6780